ArticleUnited European gastroenterology journal2025
Volumetric Changes in Perianal Fistulizing Crohn's Disease Measured by Magnetic Resonance Is Feasible and Could Be a Potential Biomarker to Predict Clinical Outcomes.
Article in United European gastroenterology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- VALIDATE-PERIANAL: an international real-world multi-centre exploratory validation of the TOpClass definition of a radiologically healed fistula in perianal fistulising Crohn's disease.Insights into imaging · 2026Article
- Real-world evaluation of MRI fistula volume as a radiological biomarker of disease activity in perianal fistulizing Crohn's disease.Journal of Crohn's & colitis · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
BACKGROUND AND
aimChanges in 3D volumetry of perianal fistulas in patients with Crohn's disease (CD) measured by MRI could be an imaging biomarker of interest. The objective of the study was to determine the value of volumetric changes in CD perianal fistulas after medical treatment to predict outcomes.
methodsThis is a retrospective single-center pilot study evaluating CD patients with active perianal fistulas who started biological therapy between 2012 and 2021. Eligible patients were those who had both pre- and post-treatment pelvic MRI and clinical follow-up of 2-5 years. Patients were categorized as clinically active or in remission based on fistula drainage. Using specific software, we calculated the 3D volume of the fistulas, and their active and fibrotic components. We evaluated MRI volumetric changes between assessments and analyzed their predictive value for clinical remission.
resultsWe included 24 patients (83.3% with complex fistulas), of which 13 were in clinical remission at the last follow-up. Logistic regression analysis identified the percentage of relative change in the volumetric active component as an independent predictor of clinical remission (OR 0.92 [0.86-0.98] p = 0.013). The area under receiver operating characteristic (ROC) curve was 85.3% (p < 0.0001). A reduction of ≥ 16% in the volumetric percentage of the active component has a sensitivity of 84.6 and specificity of 81% in predicting clinical remission during follow-up.
conclusionChanges in the 3D MRI volumetry of perianal fistulas might have value in predicting clinical remission. Specifically, the reduction in the volumetry of the active component emerges as a promising biomarker for assessing therapeutic response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.